A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results